Gain Therapeutics announces proposed public offering

* Gain Therapeutics (NASDAQ:GANX [https://seekingalpha.com/symbol/GANX]) announced on Tuesday that it is proposing to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering.
* The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering.
* The company intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease, and for general corporate purposes.
* GANX -13.52% after hours to $1.47.
* Source: Press Release [https://seekingalpha.com/pr/20167081-gain-therapeutics-announces-proposed-public-offering]

MORE ON GAIN THERAPEUTICS

* Seeking Alpha’s Quant Rating on Gain Therapeutics [https://seekingalpha.com/symbol/GANX/ratings/quant-ratings]
* Historical earnings data for Gain Therapeutics [https://seekingalpha.com/symbol/GANX/earnings]
* Financial information for Gain Therapeutics [https://seekingalpha.com/symbol/GANX/income-statement]